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MicroRNAs (miRNAs) have recently emerged as important gene regulators in Cystic Fibrosis (CF), a common monogenic disease
characterized by severe infection and inﬂammation, especially in the airway compartments. In the current study, we show that both miR-145 and
miR-494 are signiﬁcantly up-regulated in nasal epithelial tissues from CF patients compared with healthy controls (p b 0.001 and p b 0.01,
respectively) by Quantitative Real-Time PCR. Only miR-494 levels showed a trend of correlation with reduced CFTR mRNA expression and
positive sweat test values, supporting the negative regulatory role of this miRNA on CFTR synthesis. Using computational prediction algorithms
and luciferase reporter assays, SMAD family member 3 (SMAD3), a key element of the TGF-β1 inﬂammatory pathway, was identiﬁed as a target
of miR-145. Indeed, miR-145 synthetic mimics suppressed by approximately 40% the expression of a reporter construct containing the SMAD3
3′-UTR. Moreover, we observed an inverse correlation between SMAD3 mRNA expression and miR-145 in CF nasal tissues (r = −0.68,
p = 0.0018, Pearson's correlation). Taken together, these results conﬁrm the pivotal role of miRNAs in the CF physio-pathogenesis and suggest
that miRNA deregulation play a role in the airway disease severity by modulating CFTR levels as well as the expression of important molecules
involved in the inﬂammatory response. miR-494 and miR-145 may, therefore, be potential biomarker and therapeutic target to speciﬁc CF clinical
manifestations.
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Cystic Fibrosis (CF) is a common genetic disease caused
by mutations in the CFTR (Cystic Fibrosis Transmembrane
conductance Regulator) gene with more than 1500 pathogenet-
ic variants, the most prevalent being F508del [1]. CFTR is a
chloride channel, essential for maintaining sweat, digestive
juices and mucus ion balance. CFTR mutations affect many
organ systems, causing lung inflammation/infection, pancreas⁎ Corresponding author at: Department of Experimental Medicine, Viale
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http://dx.doi.org/10.1016/j.jcf.2013.03.007lishedinsufficiency, intestinal obstruction and male infertility [2].
Thick mucus in the airways is the most common clinical
manifestation with recurrent inflammation, chronic microbial
infections, followed by injury and deterioration of lung func-
tions [3]. An improper inflammatory profile has been asso-
ciated with CF, involving deregulation of TGF-β1 signaling
pathway via SMAD proteins and aberrant expression of dif-
ferent cytokines, such as interleukin (IL)-8 hypersecretion
[4–6]. MicroRNAs (miRNAs) are evolutionarily conserved,
small regulatory non-coding RNAs that negatively modulate
gene expression at the post-transcriptional level by either
repressing translation or decreasing mRNA stability [7].
Dysregulation of miRNA pathways and/or epigenetics-miRNA
regulatory circuits has been associated to both multifactorial andby Elsevier B.V. All rights reserved.
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of some miRNA-based regulatory circuitry in CFTR signaling
and CF clinical manifestations [9–12]. We measured the levels
of miR-145 and miR-494 in nasal epithelium of a panel of
CF patients and healthy controls in order to better define the
miRNA role in the CF molecular pathogenesis. Both miRNAs
are known as CFTR expression post-transcriptional regulators
[10,11]. We found that both miRNAs were significantly
over-expressed in CF tissues. Moreover, a inverse correlation
was evident between the expression of miR-145 and SMAD3 in
CF patients. A trend toward an association was also observed
between miR-494 and CFTR levels, although it did not reach
statistical significance. Our data support the crucial role of
miRNAs in the CF pathogenesis by modulating their target gene
expression.
2. Materials and methods
2.1. Sample collection
This study is comprised of 18 unrelated patients (mean age
33.1 ± 8.6 years, 11:7 male:female subjects) who received a
diagnosis of Cystic Fibrosis at the Regional Center of Cystic
Fibrosis—Policlinico Umberto I of Rome, Italy. Patients were
eligible if they were 18 years of age or older. CF cases were
F508del/F508del homozygotes (11/18) or carried at least one
F508del variant: F508del/W1282X (3/18), F508del/N1303K
(1/18), F508del/G85E (1/18), F508del/S549R(A N C) (1/18);
one individual was homozygote for CFTR mutations different
from F508del (R553X/N1303K). The segregation of CFTR
mutated alleles was verified in parents. All CF subjects shared
severe lung function impairment with a FEV1 (forced ex-
piratory volume in 1 s) mean value of 49.2% ± 16.9 and
recurrent or chronic pathogen infections, especially Pseudomonas
aeruginosa. An average value of sweat test, a measure of
CFTR-associated functionality, resulted 95.8 ± 15.5 mmol/L.
Five non-CF unrelated individuals, without known airway
diseases, were used as healthy control group. Italian patients
and controls have been fully informed about the aims of our
study; all participants freely agreed to take part to the research
and signed an institutional written informed consent. The study
underwent ethical review and approval according to local
institutional guidelines.
2.2. RNA extraction and quantitative Real Time PCR
(qRT-PCR)
Respiratory epithelial cells were obtained by brushing each
nasal cavity from patients and controls. Total RNA was extract-
ed using Trizol (Invitrogen) according to the manufacturer's
instructions. Reverse Transcription (RT) for human miR-145
and miR-494 were carried out with TaqMan MicroRNA Assay
kit (Applied Biosystem) using 20 ng RNA sample; High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems)
was used for reverse transcription of total RNA for CFTR
and SMAD3 expression analysis. Quantitative Real Time
PCR (qRT-PCR) analysis of miRNA and mRNA levels wereperformed in an Applied Biosystems 7000 Real Time PCR
machine using miRNA-specific TaqMan MGB probe
(has-miR-145, 002149; has-miR-494, 002365) and TaqMan
Gene Expression Assays (CFTR, Hs00357011_m1; SMAD3,
Hs00969210_m1). U6 small nuclear RNA (RNU6) and GAPDH
mRNA were used as endogenous controls to normalize sample
data. PCR reactions were run at 95 °C for 10 min, followed by
40 cycles at 95 °C for 15 s and 60 °C for 1 min. Each sample
was run in triplicate and the 2−ΔΔCT method was used to
calculate the relative miRNA or mRNA abundance in the
different samples compared to the mean of all control samples
represented as unitary value. qRT-PCR data were analyzed using
Data Assist software (Applied Biosystems). Experiments were
independently carried out three times.
2.3. Bioinformatic analysis
MiR-145 target genes were computationally evaluated using
common prediction algorithms provided at TargetScan (release
6.2), miRanda and DIANA-microT-CDS software searching
for conserved sites that matched the seed region of the
microRNA, obtained from miRBase database. NCBI and
UTRdb genome browsers provided information of human
SMAD3 gene (NM_005902; 3HSAR033639).
2.4. Plasmids and luciferase assay
The 3′-UTR region of SMAD3 (1081-1700 bp and 3100-
4223 bp of NM_005902) containing the predicted target sites of
miR-145 was amplified from human genomic DNA using a proof
reading Phusion High-Fidelity PCR master mix (Finnzymes)
with the following primers:
SMAD3 3′UTR-F1 5′-GCTCTAGATCTCCTGAGG TGA
AGCTTTTCC-3′ and SMAD3 3′UTR-R1 5′-GCTCTA
GACCCTGCAGATGAGGCATCAG-3′ for fragment con-
taining “seed 1” and SMAD3 3′UTR-F2 5′-GCTCTAGA
ATGAGGGCAAGGCTGCTGGC-3′ and SMAD3 3′
UTR-R2 5′-GCTCTAGA GTCTGTTTTTACACGCGGC
CAC-3′ for “seed 2”. The amplified products were inserted
into the XbaI site (underlined primer sequences) of the
pRLTK vector (Promega). Transformants were validated
by restriction digestions and direct sequencing. Luciferase
reporter constructs were termed as pSMAD3-S1-3′UTR
(620 bp) and pSMAD3-S2-3′UTR (1123 bp). HEK293 cells
(1.5 × 105) in 24-well plates were transfected with 50 ng
Renilla luciferase reporter vector (pRLTK, pSMAD3-S1-3′
UTR or pSMAD3-S2-3′UTR), 12.5 ng Firefly luciferase con-
trol vector (pGL3-SV40, Promega), 100 nM miRNA mimics
(hsa-mir-145 miRIDIANMimic MI0000461/MIMAT0000437,
has-miR-494 miRIDIAN Mimic MI0003134/MIMAT0002816
or miRIDIAN Mimic Negative Control#1 by Dharmacon) and
1.5 μl Lipofectamine 2000 (Invitrogen) following the recom-
mended conditions. Luciferase assays were performed 48 h after
transfection using the Dual Luciferase Reporter Assay System
(Promega) according to the manufacturer's protocol. Renilla/
Firefly luciferase activity was calculated for each reaction.
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and repeated three times.
2.5. Statistical analysis
Results are expressed as mean ± standard deviation (S.D.)
from at least three separate experiments. Differences between
groups were statistically determined using Student's t test.
Correlation coefficients were calculated by Pearson's cor-
relation test. A p-value of less than 0.05 was considered as
statistically significant. All statistical analyses were performed
using Excel and SPSS software.
3. Results
In order to assess the abundance of miR-145 and miR-494 in
total RNA extracted from nasal epithelia of CF patients and
healthy control subjects, we performed quantitative Real Time
PCR (qRT-PCR) experiments. Indeed, tall columnar epithelial
cells have been demonstrated to be valid surrogates for bron-
chial epithelial cells in airway functional and inflammation
studies [13,14]. The miR-relative expression was increased
at-least 1.5-fold in 13/18 (72.2%) CF samples for miR-145 and
in 14/18 of them (77.8%) for miR-494. As shown in Fig. 1A, the
mean levels of both miRNAs were significantly up-regulated in
patients compared with controls by around 5 times for miR-145
(p b 0.001) and 2.5 times for miR-494 (p b 0.01). Interestingly,
CFTR gene expression in airway nasal tissues, as judged by
mRNA level measurements, was down-regulated in CF com-
pared to controls (p b 0.001) (Fig. 1B). Using Pearson's cor-
relation test, we analyzed the relationships between miRNA
levels and CFTR expression. The abundance of CFTR transcript
was not significantly associated with any miRNA although aFig. 1. Up-regulation of miR-145 and miR-494 and down-regulation of CFTR mR
expression level of miR-145 and miR-494 between nasal epithelial tissues from CF
(**, p b 0.01; ***, p b 0.001). (B) Relative expression levels of CFTR mRNA in na
are mean ± S.D. of three separate experiments (***, p b 0.001).trend of inverse correlation was evident with the expression of
miR-494 (r = −0.42 Pearson's correlation, p = ns) but not with
of miR-145 (r = −0.19 Pearson's correlation, p = ns). The
expression of miR-494 was weakly related with values of sweat
test (r = −0.50 Pearson's correlation, p = 0.03) supporting the
observation that this miRNA may be directly involved in the
post-transcriptional regulation of CFTR expression and activity
[10,11]. In order to identify the potential target(s) of miR-145 in
relation with CF, we searched miR-databases using different
prediction algorithms such as TargetScan, PicTar and miRanda.
The most interesting hit was SMAD3 gene, which codes
for a protein involved in the immunosuppression and anti-
inflammatory response mediated by TGF-β1 [15]. As shown in
Fig. 2A, SMAD3 3′UTR has two putative conserved binding site
for the miR-145 seed region at position 1397–1404 (S1) and
3925–3931 (S2). SMAD3 altered expression in different CF
model systems, such as Cftr -/- mouse nasal epithelium and
human tracheal epithelial cells has been extensively reported
[4,5]. We generated two different reporter vectors containing
either the putative S1 or the S2 binding sites of the human
SMAD3 3′UTR, downstream of the Renilla luciferase open-
reading-frame. When HEK293 cells were transfected with
miR-145 mimics (Fig. 2B), we observed a significant reduction
in both pSMAD3-3′UTR luciferase activity, compared to
microRNA negative control (miR-Ctr). The reduction in lucif-
erase activity was about 40% when pSMAD3-3′UTR-S1 was
co-transfected and 30% with pSMAD3-3′UTR-S2 (p b 0.01
and p b 0.001, respectively). No significant repression was
obtained when miR-494 was co-transfected instead of miR-145
confirming the specificity of the miR-responsive elements in the
SMAD3 3′UTR (Fig. 2B). Considering that miR-145 is
up-regulated in CF nasal epithelia and SMAD3 may be a target
for miR-145, we analyzed the expression of SMAD3 in CF andNA in nasal epithelial cells from CF patients. (A) Comparison of the average
and non-CF individuals. Data are mean ± S.D. of three separate experiments
sal epithelial tissues from CF patients compared with non-CF individuals. Data
Fig. 2. Mir-145 directly target the SMAD3 3′-UTR. (A) Schematic representation of the SMAD3 3′UTR and miRNAs (rectangles). Ribonucleotide sequences of the
putative miR-145 responsive elements in SMAD3 3′UTR paired with the mature human miR-sequence (from TargetScan 6.2 database). Numbers indicate the
predicted miR-145 sequences (in bold) using the numbering of the human SMAD3 3′UTR (3HSAR033639 from UTRdb database). (B) At 48 h post-transfection,
luciferase activity was measured and normalized to the Firefly control in HEK293 cells transfected with pSMAD3-S1-3′UTR or pSMAD3-S2-3′UTR vector together
with miR-145 or a negative control miRNA (miR-494 or miR-Ctr). Data are presented as the normalized activity of miR-transfected cells relative to miR-Ctr. These
results represent the mean of three independent experiments ± S.D. The significance levels were obtained by Student's t test: **, p b 0.01; ***, p b 0.001 compared
with the control miRNA.
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mRNA levels were significantly down-regulated in airway
tissues from CF patients compared with controls (p b 0.01).
Furthermore, we observed a significant inverse correlation
between miR-145 and SMAD3 mRNA levels (r = −0.68
Pearson's correlation, p = 0.0018) (Fig. 3B).
In summary, these results show that miR-145 and miR-494
are differently expressed in CF versus non-CF nasal epithelial
tissues and, although not statistically significant, a trend for
inverse miR-494/CFTR relationship is observed. Notably,
miR-145 is able to regulate SMAD3 expression suggestingFig. 3. Down-regulation of SMAD3 mRNA correlates with elevated levels of miR-1
from CF and non-CF individuals Histograms represent the average value ± S.D. of t
miR-145 and SMAD3 mRNA expression levels in samples from 18 CF patients (Pethat an altered SMAD3-mediated inflammatory pathway may
be directly correlated to improper levels of miR-145 in CF
disease.
4. Discussion
MicroRNAs have emerged as important regulatory mole-
cules involved in a broad range of molecular mechanisms and
their deregulation has been implicated in different genetic
diseases, including Cystic Fibrosis (CF) [9–12]. We found that
miR-145 and miR-494 levels were significantly over-expressed45 in CF patients. (A) Reduced of SMAD3 expression in nasal epithelial tissues
hree independent experiments (**, p b 0.01). (B) Negative correlation between
arson's correlation analysis).
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dividuals. Specifically, miR-494 levels were about 2.5-fold
higher in CF samples with a trend for inverse correlation
between this miRNA and CFTR levels. Although not sta-
tistically significant, this evidence suggests that miR-494 may
behave as a genetic modifier for the CF clinical manifestations
also modulating the CFTR gene expression, as an additional
level of control over CFTR mutations. These results are in
agreement with the observations that miR-494 mimic over-
expression is able to directly suppress CFTR mRNA [10,11].
Beside the common F508del variant, our CF patients carry
missense and nonsense alterations in the CFTR gene. Indeed,
different studies have shown that the effect of nonsense
mutations on CFTR mRNA levels are very variable [16] and
nonsense-mediated decay (NMD) is addressed as the major
mechanism for rapid degradation of aberrant transcripts harbor-
ing premature termination codons. Interestingly, microRNAs
have recently been defined as important regulators of the NMD
efficiency [17]. So, aberrant expression of specific miRNAs in
CF patients could directly or indirectly have important implica-
tions on CFTR mRNA levels. Up-regulation of miR-494 in
asthmatic samples [18] and direct influence in cell cycle
progression of primary murine bronchial epithelial cells exposed
to carcinogens [19] suggest that miR-494 altered levels have
effects mainly in the lung compartment.
We also observed that a second miRNA, miR-145, was
increased in nasal airway cells of CF versus non-CF in-
dividuals. The expression increase of miR-145 was significant-
ly correlated with a consistent decrease of SMAD3 mRNA, a
potential target of this miRNA. SMAD3 is a key component of
the immune system which plays a protective effect against
infection and inflammation [15]. SMAD3 expression is de-
creased in CF nasal epithelial cells [5,6] suggesting a cor-
relation with the associated increase of miR-145. The direct
silencing of SMAD3 gene provides a possible explanation for
the improper inflammatory response and to such an airway
remodeling/fibrosis as common in CF patients. Since SMAD3
has been proposed to play a role in the TGF-β1-mediated
negative regulation of the NF-kB/IL-8 pathway [20], a di-
minished SMAD3 expression may contribute to the hyper-
inflammation observed in the CF airways. The relationship
between miR-145 and SMAD3 is well demonstrated by the
luciferase assays showing a meaningful decreased activity of
SMAD3 3′UTR-reporter constructs after miR-145 transfection.
The reduced expression of SMAD3 is consistent with previous
findings in cultured cell models of CF as well as in the nasal
epithelium of cftr -/- mice [4] and suggests that miR-145 control
pathway could represent a potential therapeutic target aimed
to restore SMAD3-mediated TGF-β1 signaling abnormalities
identified in CF.
In conclusion, the present study demonstrates the impor-
tance of miRNA-related pathways may have as modulatory
factors in CF clinical manifestations. In particular, the dis-
covery of miR-145 and miR-494 altered levels in CF patients
and the evidence of a strong inverse correlation with SMAD3
gene expression suggests the possibility of a coordinated
network of gene expression control by microRNAs. miR-145and miR-494 expression seem to have particular importance in
airway tissue functions, as potential modulators pathological
events, such as increased susceptibility to infections, chronic
airways inflammation and response to specific therapies. Future
studies will be planned to determine the molecular pathways of
miR-494/miR-145 in cell line models and to analyze the
correlation between miRNA abundance and specific symptoms
in a wide cohort of CF patients, especially in CF relatives (twins
or siblings) sharing the same CFTR pathological alleles but
different phenotypes. Ameliorating the acknowledgments of
miRNA regulators, downstream targets and signaling pathways
in Cystic Fibrosis is essential for elucidating complex regulatory
networks that are critical for the disease biology and severity.
The identification of CF-related microRNAs potentially offer
novel therapeutic applications to ameliorate specific clinical
aspects and response to therapy in disease complications.
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